Loading
Life sciences · Journal article
European Journal of Drug Metabolism and Pharmacokinetics · September 19, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Personalized therapy strategies based on patient characteristics and informative biomarkers may reduce the risk of chemotherapy-related toxicity. The aim of study was to identify changes in plasma homocysteine (HCy), 5-methyltetrahydrofolate (MTHF), pyridoxal phosphate (PLP), 5-fluorouracil (5-FU), fluorodeoxyuridine (FdUr), and deoxyuridine (dUr) levels, as well as salivary levels of uracil (Ura) and dihydrouracil (UH 2 ) in patients with colorectal cancer (CRC) during adjuvant 5-FU-based chemotherapy. Further, the aim was to evaluate whether these metabolites have the potential to be utilized as risk markers for chemotherapy-related toxicity. Blood and saliva samples were collected from 24 patients immediately before treatment initiation on days 1 and 2 of cycle 1 (C1-1, C1-2) and cycle 2 (C2-1, C2-2). Additional blood samples were collected 10 and 30 min after 5-FU administration to enable calculation of area under the curve (AUC) values. HCy levels were determined by the chemiluminescent microparticle enzyme immunoassay method, Ura and UH 2 levels by HPLC, and MTHF, PLP, 5-FU, FdUr, and dUr levels by LC-MS/MS. Significant shifts in metabolite profiles were observed across both chemotherapy cycles, with most metabolites failing to return to baseline levels between cycles. HCy levels declined progressively, whereas MTHF, PLP, FdUr, and dUr increased. Men had higher HCy levels than women. HCy levels correlated positively with age in women at baseline ( r = 0.65, p = 0.029), a relationship not seen in men. HCy also correlated positively with the interval between surgery and initiation of chemotherapy during Cycle 1 ( r = 0.60, p = 0.0024 at C1-2). Plasma 5-FU rose at C1-2 in both sexes but diverged during Cycle 2, decreasing in men while continuing to rise in women. Twelve patients required 5-FU dose reduction. These patients had higher plasma HCy and lower salivary Ura at C1-1 and C2-1, along with greater increases in Ura and 5-FU between C2-2 and C1-2 (Δ-values). A predictive model incorporating ΔUra, Δ5-FU, and sex strongly predicted need for 5-FU dose reduction ( p < 0.0001). Significant alterations in metabolite levels occur during the first two cycles of adjuvant 5-FU-based chemotherapy, potentially contributing to treatment-related toxicity. Moderate associations between HCy levels, patient age, and timing of chemotherapy initiation suggest that patient-related factors may influence one-carbon metabolism during 5-FU/LV therapy. Higher Ura and 5-FU levels in women during Cycle 2 may contribute to sex-related differences in treatment-related toxicity. Changes in Ura and 5-FU levels between treatment cycles (ΔUra and Δ5-FU AUC) might be particularly informative for guiding individualized 5-FU dose adjustments, especially when interpreted in the context of patient sex.